The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Biocoryl     4-amino-N-(2- diethylaminoethyl)benzamide

Synonyms: Rhythmin, Novocamid, Procamide, Procanbid, Pronestyl, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Novocainamide


Psychiatry related information on Novocainamide


High impact information on Novocainamide


Chemical compound and disease context of Novocainamide


Biological context of Novocainamide


Anatomical context of Novocainamide


Associations of Novocainamide with other chemical compounds


Gene context of Novocainamide


Analytical, diagnostic and therapeutic context of Novocainamide


  1. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. Totoritis, M.C., Tan, E.M., McNally, E.M., Rubin, R.L. N. Engl. J. Med. (1988) [Pubmed]
  2. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. Minardo, J.D., Heger, J.J., Miles, W.M., Zipes, D.P., Prystowsky, E.N. N. Engl. J. Med. (1988) [Pubmed]
  3. Transplacental cardioversion of fetal supraventricular tachycardia with procainamide. Dumesic, D.A., Silverman, N.H., Tobias, S., Golbus, M.S. N. Engl. J. Med. (1982) [Pubmed]
  4. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide. Kleinman, S., Nelson, R., Smith, L., Goldfinger, D. N. Engl. J. Med. (1984) [Pubmed]
  5. Development of antibodies to ribonucleoprotein following short-term therapy with procainamide. Winfield, J.B., Koffler, D., Kunkel, H.G. Arthritis Rheum. (1975) [Pubmed]
  6. Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide. Shoenfeld, Y., Vilner, Y., Reshef, T., Klajman, A., Skibin, A., Kooperman, O., Kennedy, R.C. J. Clin. Immunol. (1987) [Pubmed]
  7. Possible case of procainamide-induced intrahepatic cholestatic jaundice. Chuang, L.C., Tunier, A.P., Akhtar, N., Levine, S.M. The Annals of pharmacotherapy. (1993) [Pubmed]
  8. Pharmacokinetics of N-acetylprocainamide. Atkinson, A.J., Ruo, T.I. Angiology. (1986) [Pubmed]
  9. Procainamide: autoimmune phenomena and acetylator phenotype. Bernstein, R.E. N. Engl. J. Med. (1985) [Pubmed]
  10. Disruption of positive selection of thymocytes causes autoimmunity. Kretz-Rommel, A., Rubin, R.L. Nat. Med. (2000) [Pubmed]
  11. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D., Lehmann, M.H. JAMA (1993) [Pubmed]
  12. Drug-induced pancreatitis: a critical review. Mallory, A., Kern, F. Gastroenterology (1980) [Pubmed]
  13. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Stec, G.P., Lertora, J.J., Atkinson, A.J., Nevin, M.J., Kushner, W., Jones, C., Schmid, F.R., Askenazi, J. Ann. Intern. Med. (1979) [Pubmed]
  14. Reactive hypoglycemia and insulin autoantibodies in drug-induced lupus erythematosus. Blackshear, P.J., Rotner, H.E., Kriauciunas, K.A., Kahn, C.R. Ann. Intern. Med. (1983) [Pubmed]
  15. Agranulocytosis, procainamide, and phenytoin. Fleet, S. Ann. Intern. Med. (1984) [Pubmed]
  16. Effects of lidocaine and procainamide on normal and abnormal intraventricular electrograms during sinus rhythm. Schmitt, C.G., Kadish, A.H., Marchlinski, F.E., Miller, J.M., Buxton, A.E., Josephson, M.E. Circulation (1988) [Pubmed]
  17. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. Galanakis, D.K., Newman, J., Summers, D. JAMA (1978) [Pubmed]
  18. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. Yung, R., Powers, D., Johnson, K., Amento, E., Carr, D., Laing, T., Yang, J., Chang, S., Hemati, N., Richardson, B. J. Clin. Invest. (1996) [Pubmed]
  19. Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. Rubin, R.L., Curnutte, J.T. J. Clin. Invest. (1989) [Pubmed]
  20. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients. Vlasses, P.H., Rocci, M.L., Porrini, K.A., Greenspon, A.J., Ferguson, R.K. Ann. Intern. Med. (1983) [Pubmed]
  21. Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro. Ochi, T., Goldings, E.A., Lipsky, P.E., Ziff, M. J. Clin. Invest. (1983) [Pubmed]
  22. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. Quddus, J., Johnson, K.J., Gavalchin, J., Amento, E.P., Chrisp, C.E., Yung, R.L., Richardson, B.C. J. Clin. Invest. (1993) [Pubmed]
  23. Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome. Bluestein, H.G., Zvaifler, N.J., Weisman, M.H., Shapiro, R.F. Lancet (1979) [Pubmed]
  24. Iontophoretic transmyocardial drug delivery. A novel approach to antiarrhythmic drug therapy. Avitall, B., Hare, J., Zander, G., Bockoff, C., Tchou, P., Jazayeri, M., Akhtar, M. Circulation (1992) [Pubmed]
  25. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. Alikhani-Koopaei, R., Fouladkou, F., Frey, F.J., Frey, B.M. J. Clin. Invest. (2004) [Pubmed]
  26. Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships. Jaillon, P., Winkle, R.A. Circulation (1979) [Pubmed]
  27. Hypolipidemic effect of type Ia antiarrhythmic agents in postinfarction patients. Boden, W.E., Moss, A.J., Oakes, D. Circulation (1992) [Pubmed]
  28. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Lin, X., Asgari, K., Putzi, M.J., Gage, W.R., Yu, X., Cornblatt, B.S., Kumar, A., Piantadosi, S., DeWeese, T.L., De Marzo, A.M., Nelson, W.G. Cancer Res. (2001) [Pubmed]
  29. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Grant, D.M., Blum, M., Beer, M., Meyer, U.A. Mol. Pharmacol. (1991) [Pubmed]
  30. Role of CYP2D6 in the N-hydroxylation of procainamide. Lessard, E., Fortin, A., Bélanger, P.M., Beaune, P., Hamelin, B.A., Turgeon, J. Pharmacogenetics (1997) [Pubmed]
  31. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. Yabuuchi, H., Tamai, I., Nezu, J., Sakamoto, K., Oku, A., Shimane, M., Sai, Y., Tsuji, A. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  32. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide. Ridley, J.M., Milnes, J.T., Benest, A.V., Masters, J.D., Witchel, H.J., Hancox, J.C. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  33. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. Woosley, R.L., Drayer, D.E., Reidenberg, M.M., Nies, A.S., Carr, K., Oates, J.A. N. Engl. J. Med. (1978) [Pubmed]
  34. Severe neutropenia associated with sustained-release procainamide. Ellrodt, A.G., Murata, G.H., Riedinger, M.S., Stewart, M.E., Mochizuki, C., Gray, R. Ann. Intern. Med. (1984) [Pubmed]
WikiGenes - Universities